ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Takayasu arteritis"

  • Abstract Number: 013 • 2020 Pediatric Rheumatology Symposium

    A Preliminary Data-driven Anatomic Classification for Childhood Takayasu Arteritis (cTA)

    Ellen Go1, Simon Eng 2, David Cabral 3 and Rae Yeung 1, 1The Hospital for Sick Children, Toronto, Canada, 2Toronto, Canada, 3BC Children's Hospital and University of British Columbia, Vancouver, British Columbia, Canada

    Background/Purpose: The pattern of arterial involvement and disease severity varies in those affected with cTA. Distinct imaging patterns that have some congruence with clinical phenotype…
  • Abstract Number: 062 • 2020 Pediatric Rheumatology Symposium

    Is Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) a Reliable Tool for Detecting Vascular Activity in Treated Childhood-Onset Takayasu’s Arteritis (C-TA)? A Multicenter Study

    Gleice Russo1, Rosa Pereira 2, Nadia Aikawa 3, Clovis Silva 4, Lucia Campos 5, Ana Paula Sakamoto 6, Alexandre Souza 7 and Maria Teresa Terreri 4, 1Universidade Federal de Sao Paulo, Sao Paulo, Sao Paulo, Brazil, 2University of São Paulo, Sao Paulo, Brazil, 3University of Sao Paulo, Sao Paulo, Brazil, 4Sao Paulo, Brazil, 5children's institute, Sao Paulo, Brazil, 6São Paulo, Brazil, 7UNIFESP-EPM, São Paulo, Brazil

    Background/Purpose: The improving therapeutic approach towards childhood-onset Takayasu’s arteritis (c-TA) has decreased the mortality rate over the years and increased concerns on how to improve…
  • Abstract Number: 106 • 2020 Pediatric Rheumatology Symposium

    Childhood-onset Takayasu Arteritis: A Single Center Case Series of Atypical and Varied Presentations

    Uptej Khalsa1 and Imelda Balboni 1, 1Stanford University, Palo Alto, California

    Background/Purpose: Childhood-onset Takayasu arteritis is a rare inflammatory vessel disease that predominantly affects the aorta and its major branches. Clinical presentation at disease onset can…
  • Abstract Number: 1964 • 2019 ACR/ARP Annual Meeting

    A Role for Microbiota in the Pathophysiology of Takayasu Arteritis (TAK) and Giant Cell Arteritis (GCA)

    Anne Desbois1, Dragos Ciocan 2, David Saadoun 1, Gabriel Perlemuter 3 and Patrice Cacoub 4, 1GHPS, Paris, France, 2Hôpital Antoine Beclere, Clamart, France, 3Hôpital Clamart, Paris, France, 4AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, F-75013, Paris, France, Paris, France

    Background/Purpose: The pathogenesis of Large Vessel Vasculitis (LVV) is not well understood. There is increasing evidence of a close link between intestinal dysbiosis and systemic…
  • Abstract Number: 2740 • 2019 ACR/ARP Annual Meeting

    Takayasu Arteritis Associated Risk Locus in IL6 Represses the Anti-inflammatory Gene GPNMB Through Chromatin Looping and Recruiting MEF2-HDAC Complex

    Xiufang Kong 1 and Amr Sawalha2, 1University of Michigan & Fudan University, Ann Arbor, MI, 2University of Pittsburgh & University of Michigan, Pittsburgh, PA

    Background/Purpose: Previous work has revealed a genetic association between Takayasu arteritis and a non-coding genetic variant in an enhancer region within IL6 (rs2069837 A/G). The…
  • Abstract Number: 2919 • 2019 ACR/ARP Annual Meeting

    Endothelial Protein C Receptor and Scavenger Receptor Class B Type 1 Negatively Regulate Vascular Inflammation and Are Major Autoantigens in Takayasu Arteritis

    Tomoyuki Mutoh1, Tsuyoshi Shirai 1, Tomonori Ishii 2, Yuko Shirota 3, Hideo Harigae 1 and Hiroshi Fujii 1, 1Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan, 2Tohoku University Hospital, Sendai, Japan, 3Department of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University, Sendai, Japan

    Background/Purpose: Takayasu arteritis (TAK) is a chronic vasculitis which predominantly affects large vessels. Although anti-endothelial cell antibodies (AECA) had been reported to be involved in…
  • Abstract Number: 2920 • 2019 ACR/ARP Annual Meeting

    Comparison of Arterial Patterns of Disease in Takayasu’s Arteritis and Giant Cell Arteritis

    K Bates Gribbons1, Cristina Ponte 2, Anthea Craven 3, David Cuthbertson 4, Simon Carette 5, Gary S. Hoffman 6, Nader A. Khalidi 7, Curry L. Koening 8, Carol Langford 9, Kathleen Maksimowicz-McKinnon 10, Carol A. McAlear 11, Paul Monach 12, Larry Moreland 13, Christian Pagnoux 14, Kaitlin Quinn 15, Joanna Robson 16, Philip Seo 17, Antoine Sreih 18, Ravi Suppiah 19, Kenneth Warrington 20, Steven Ytterberg 21, Raashid Luqmani 3, Richard Watts 22, Peter Merkel 18 and Peter C. Grayson 23, 1National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 2Department of Rheumatology, Hospital de Santa Maria, Lisbon, Portugal, 3University of Oxford, Oxford, United Kingdom, 4University of South Florida, Tampa, FL, 5Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, Canada, 6Cleveland Clinic Foundation, Cleveland, OH, 7McMaster University, Hamilton, ON, Canada, 8University of Utah Hospital, Salt Lake City, UT, 9Cleveland Clinic, Cleveland, OH, 10Henry Ford Hospital, Wayne State University, Detroit, MI, 11University of Pennsylvania - VCRC Project Manager, Philadelphia, PA, 12Brigham and Women's Hospital, Boston, MA, 13University of Pittsburgh, PITTSBURGH, PA, 14Mount Sinai Hospital and University Health Network, Toronto, ON, Canada, 15Georgetown University Hospital/National Institutes of Health, Washington, DC, 16Faculty of Health and Applied Sciences, University of the West of England, Bristol, United Kingdom, 17Johns Hopkins Medicine, Baltimore, MD, 18University of Pennsylvania, Philadelphia, PA, 19Department of Rheumatology, Auckland District Health Board, Auckland, New Zealand, 20Mayo Clinic Rochester, Rochester, MN, 21Mayo Clinic College of Medicine, Rochester, MN, 22Norwich Medical School, University of East Anglia, Norwich, United Kingdom, 23National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health, Bethesda, MD, Bethesda, MD

    Background/Purpose: Current classification criteria differentiate between Takayasu’s arteritis (TAK) and giant cell arteritis (GCA), the two most common forms of large-vessel vasculitis, based primarily on…
  • Abstract Number: 15 • 2019 ACR/ARP Annual Meeting

    CYR61/TGF-β Axis Promotes Adventitial Fibrosis of Takayasu Arteritis in the IL-17 Mediated Inflammatory Microenvironment

    Lili Ma1, Xiufang Kong 2, Xiaomeng Cui 1, Sifan Wu 1, Yujiao Wang 1 and Lindi Jiang 1, 1Zhongshan hospital, Fudan University, Shanghai, China (People's Republic), 2University of Michigan & Fudan University, Ann Arbor, MI

    Background/Purpose: As a novel proinflammatory and potential profibrotic factor, the role of CYR61 on the vascular fibrosis of Takayasu arteritis (TA) has not been investigated.Methods:…
  • Abstract Number: 741 • 2019 ACR/ARP Annual Meeting

    Vascular Damage Is Less Present in an Early Inception Cohort in Takayasu’s Arteritis

    Fatma Alibaz-Oner1, 1Marmara University Faculty of Medicine,Department of Rheumatology,Istanbul,Turkey, Istanbul, Turkey

    Background/Purpose: There is only retrospective and very limited data for the long term prognosis of Takayasu's Arteritis (TAK), a rare large-vessel vasculitis. In this study,…
  • Abstract Number: 743 • 2019 ACR/ARP Annual Meeting

    Association Between Acute-phase Reactants, interleukin-6(IL6), Tumor Necrosis Factor-a(TNFa) and Disease Activity in Takayasu’s Arteritis During Follow-up with Repeated Evaluation of Vascular Imaging Manifestations

    JIng LI1, Yunjiao Yang 1, Yanhong WANG 2, Jiuliang Zhao 1, Mengtao Li 3, Xinping Tian 1 and Xiaofeng Zeng 1, 1Peking Union Medical College Hospital, Beijing, China (People's Republic), 2Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, School of Basic Medicine, Beijing, China (People's Republic), 3Dept. of Rheumatology, Peking Union Medical College Hospital (West Campus), Beijing, China, Beijing, China (People's Republic)

    Background/Purpose: To investigate the laboratory indicators of disease activity during follow-up of Takayasu’s arteritis(TAK).Methods: Electronic data of 588 patients with TAK enrolled in the Chinese…
  • Abstract Number: 746 • 2019 ACR/ARP Annual Meeting

    Childhood-Onset Takayasu’s Arteritis (TAK) Is Clinically More Active, However Has Similar Cumulative Damage Compared to Adult-Onset TAK

    Murat Karabacak1, Sema Kaymaz-Tahra 2, Sezgin Sahin 3, Mehmet Yıldız 4, Amra Adrovic 5, Kenan Barut 6, Haner Direskeneli 7, Ozgur Kasapcopur 8 and Fatma Alibaz-Oner 1, 1Marmara University Faculty of Medicine,Department of Rheumatology,Istanbul,Turkey, Istanbul, Turkey, 2Marmara University School of Medicine, Division of Rheumatology, Istanbul, Istanbul, Turkey, 3Department of Pediatric Rheumatology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey, Istanbul, Istanbul, Turkey, 4Department of Pediatric Rheumatology, Istanbul University Cerrahpasa, Istanbul, Istanbul, Turkey, 5Department of Pediatric Rheumatology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey, Istanbul, Turkey, 6Department of Pediatric Rheumatology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey, İstanbul, Istanbul, Turkey, 7Marmara University, School of Medicine, Division of Rheumatology, Istanbul, Turkey, 8Department of Pediatric Rheumatology, Istanbul University-Cerrahpasa, Istanbul, Turkey, Istanbul, Turkey

    Background/Purpose: Childhood-onset Takayasu’s Arteritis (TAK) may differ in presentation, clinical manifestations and treatment, as previously shown1. We aimed to compare the clinical manifestations, vascular involvement…
  • Abstract Number: 748 • 2019 ACR/ARP Annual Meeting

    Takayasu Arteritis and Sacroiliitis: A Case Control Study in 28 Patients of a Single Italian Center

    Paola Toniati1, Francesca Regola 1, Franco Franceschini 1, Giovanni Bosio 2 and Angela Tincani 3, 1Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Brescia, Italy, Brescia, Italy, 2Nuclear Medicine Unit, ASST Spedali Civili of Brescia, Brescia, Italy, Brescia, Italy, 3Rheumatology and Clinical Immunology, Spedali Civili and Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy, Brescia, Italy

    Background/Purpose: A lot of clinical case descriptions about spondyloarthropathy in TAK patients were reported. Recently, a paper about an increased incidence of spondyloarthropathy in TAK…
  • Abstract Number: 752 • 2019 ACR/ARP Annual Meeting

    Drug Retention and Discontinuation Reasons Between Seven Biologics in Patients with Takayasu Arteritis

    Corrado Campochiaro1, Alessandro Tomelleri 2, Silvia Sartorelli 3, Giulio Cavalli 2, De Luca Giacomo 4, Elena Baldissera 2 and Lorenzo Dagna 2, 1Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy, 2Unit of Immunology, Rheumatology, Allergy and Rare Diseases. IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University., Milan, Italy, 3Vita-Salute San Raffaele University, IRCCS San Raffaele Hospital, Milan, Italy, 4Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy., Milan, Italy

    Background/Purpose: Takayasu's arteritis (TA) is a large vessel vasculitis affecting mainly young women. Biologic agents are currently use to treat refractory TA patients but no…
  • Abstract Number: 753 • 2019 ACR/ARP Annual Meeting

    Initial Clinical Presentation Is Associated with Outcome in Takayasu’s Arteritis

    Kaitlin Quinn1, K Bates Gribbons 2, Elaine Novakovich 3 and Peter C. Grayson 4, 1Georgetown University Hospital/National Institutes of Health, Washington, DC, 2National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 3National Institutes of Health, Bethesda, MD, 4National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health, Bethesda, MD, Bethesda, MD

    Background/Purpose: The natural history of Takayasu’s arteritis (TAK) remains poorly characterized.  A “triphasic” pattern of disease has been proposed where constitutional symptoms precede vascular inflammation…
  • Abstract Number: 757 • 2019 ACR/ARP Annual Meeting

    Long-term Clinical Course and Outcomes of 2013 Patients with Takayasu Arteritis

    Hajime Yoshifuji1, Haruhito Uchida 2, Yoshikazu Nakaoka 3, Takahiko Sugihara 4, Mitsuaki Isobe 5 and Masayoshi Harigai 6, 1Kyoto University, Kyoto, Japan, 2Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, 3National Cerebral and Cardiovascular Center Research Institute, Osaka, Japan, 4Tokyo Medical and Dental University, Tokyo, Japan, 5Sakakibara Heart Institute, Tokyo, Japan, 6Department of Rheumatology, Tokyo Women's Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan

    Background/Purpose: Takayasu arteritis (TAK) occurs at a young age and has a long-term clinical course. Progression of arterial stenosis or dilatation leads to organ dysfunction.…
  • 1
  • 2
  • 3
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology